Caribou Biosciences
Genome-edited allogeneic cell therapies
- Sector
- Biotech
- Headquarters
- BERKELEY, CA
- Founded
- 2011
- Latest Form D
- $115M, Mar 2021
- Total capital
- $132M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $132M
- 3 Form D · last Mar 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 20
- 20 pending · first 2021
- Rank in peer group#5 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$115M
- Private capital raisedForm D · SEC · 2nd filing$14.5M
- Private capital raisedForm D · SEC · 1st filing$2.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#5 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew MayExecutive OfficerNamed in SEC Form D filings
- Barbara G. McClungExecutive OfficerNamed in SEC Form D filings
- Jason B. O'ByrneExecutive OfficerNamed in SEC Form D filings
- Jeffrey G. Long-McGieDirectorNamed in SEC Form D filings
- Jenny RookeDirectorNamed in SEC Form D filings
- Natalie R. SacksDirectorNamed in SEC Form D filings
Show all 13 people
- Philip E. AustinDirectorNamed in SEC Form D filings
- Rachel E. HaurwitzExecutive Officer, DirectorNamed in SEC Form D filings
- Robert E. WeisskoffDirectorNamed in SEC Form D filings
- Rodolphe E. BarrangouDirectorNamed in SEC Form D filings
- Santhosh G. PalaniDirectorNamed in SEC Form D filings
- Steven B. KannerExecutive OfficerNamed in SEC Form D filings
- Un G. Kwon-CasadoExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 20 granted of 40- GrantedCompositions And Methods Of Nucleic Acid-targeting Nucleic AcidsUSPTOUS 12,686,865
- GrantedDual Guide Crispr Hybrid Dna/rna Polynucleotides And Methods Of UseUSPTOUS 12,644,138
- PendingEngineered Cascade Components And Cascade ComplexesUSPTOApplication 18926929
Show all 40 patent records
- Compositions And Methods Of Nucleic Acid-targeting Nucleic AcidsJul 21, 2026 · US 12,686,865Granted
- Dual Guide Crispr Hybrid Dna/rna Polynucleotides And Methods Of UseJun 2, 2026 · US 12,644,138Granted
- Engineered Cascade Components And Cascade ComplexesMar 12, 2026 · Application 18926929Pending
- Cytokine-receptor Fusions For Immune Cell StimulationFeb 5, 2026 · Application 18868054Pending
- Compositions And Methods Of Nucleic Acid-targeting Nucleic AcidsJan 15, 2026 · Application 19020506Pending
- Crispr Hybrid Dna/rna Polynucleotides And Methods Of UseDec 11, 2025 · Application 19016766Pending
- ANTI-ROR1 Antibody And ROR1-TARGETING Engineered CellsDec 9, 2025 · US 12,492,264Granted
- Treatment Of Autoimmune Diseases With Engineered Immune CellsNov 13, 2025 · Application 18390978Pending
- ANTI-ROR1 Antibody And ROR1-TARGETING Engineered CellsNov 6, 2025 · Application 18868087Pending
- ANTI-CLL-1 Chimeric Antigen Receptors, Engineered Cells And Related MethodsOct 30, 2025 · Application 18842608Pending
- Therapeutic Applications Of Crispr Type V SystemsOct 23, 2025 · Application 18855884Pending
- Modified Cascade Ribonucleoproteins And Uses ThereofOct 23, 2025 · Application 19020458Pending
- Compositions And Methods Of Nucleic Acid-targeting Nucleic AcidsOct 16, 2025 · Application 19020523Pending
- Humanized Bcma Antibody And Bcma-car-t CellsOct 7, 2025 · US 12,435,152Granted
- A Method Of Capturing Crispr Endonuclease Cleavage ProductsSep 16, 2025 · US 12,416,045Granted
- Modified Cascade Ribonucleoproteins And Uses ThereofJul 17, 2025 · Application 19020478Pending
- Modified Cascade Ribonucleoproteins And Uses ThereofJul 10, 2025 · Application 19020491Pending
- Humanized Bcma Antibody And Bcma-car-t CellsMay 22, 2025 · Application 19029988Pending
- Treatment Of Autoimmune Diseases With Engineered Immune CellsMar 20, 2025 · Application 18965147Pending
- Engineered Cascade Components And Cascade ComplexesFeb 18, 2025 · US 12,227,776Granted
- Dna-containing Polynucleotides And Guides For Crispr Type V Systems, And Methods Of Making And Using The SameJan 23, 2025 · Application 18134406Pending
- Exonuclease-coupled Real-time Endonuclease Activity AssayJan 16, 2025 · Application 18704687Pending
- ANTI-ROR1 Chimeric Antigen Receptors (cars), Cells Expressing The Cars And Related MethodsOct 24, 2024 · Application 18477232Pending
- Suicide Module Compositions And MethodsOct 1, 2024 · US 12,103,956Granted
- Modified Cascade Ribonucleoproteins And Uses ThereofMay 30, 2024 · Application 18422843Pending
- Compositions And Methods Of Nucleic Acid-targeting Nucleic AcidsMay 23, 2024 · Application 18320355Pending
- Modified Cascade Ribonucleoproteins And Uses ThereofMar 26, 2024 · US 11,939,604Granted
- ANTI-ROR1 Antibody And ROR1-TARGETING Engineered CellsMar 19, 2024 · US 11,932,703Granted
- Engineered Cascade Components and Cascade ComplexesJan 17, 2023 · US 11,555,181Granted
- Engineered Nucleic Acid-targeting Nucleic AcidsNov 22, 2022 · US 11,505,808Granted
- Crispr Abasic Restricted Nucleotides And Crispr Accuracy Via AnalogsNov 3, 2022 · Application 17725324Pending
- Humanized Bcma Antibody And Bcma-car-t CellsOct 18, 2022 · US 11,472,884Granted
- Methods Of Use Of Crispr CPF1 Hybrid Dna/rna PolynucleotidesOct 4, 2022 · US 11,459,588Granted
- Compositions And Methods Of Nucleic Acid-Targeting Nucleic AcidsApr 26, 2022 · US 11,312,953Granted
- Humanized Bcma Antibody And Bcma-car-t CellsApr 12, 2022 · US 11,299,549Granted
- Crispr Hybrid Dna/rna Polynucleotides And Methods Of UseFeb 1, 2022 · US 11,236,364Granted
- Engineered Nucleic-Acid Targeting Nucleic AcidsJan 18, 2022 · US 11,225,649Granted
- METHODS FOR USING DNA REPAIR FOR CELL ENGINEERING (as amended)Oct 26, 2021 · US 11,155,814Granted
- Bcma-car-natural Killer (nk) Cells And Methods Related TheretoOct 12, 2021 · US 11,142,583Granted
- Compositions And Methods Of Engineered CRISPR-CAS9 Systems Using Split-nexus CAS9-ASSOCIATED PolynucleotidesSep 7, 2021 · US 11,111,506Granted
Related companies, and why
- Cyteir Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Nuvalent, Inc.Similar federal contract value in Biotech · null in contracts
- Electra TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Sirnaomics, Inc.Similar federal contract value in Biotech · null in contracts
- Terrestrial Bio, Inc.Similar federal contract value in Biotech · null in contracts
- iTeos TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .